TDO2 overexpression was shown to suppress anti-tumor immune responses in mouse models [10], and PD-L1, an immune checkpoint, was shown to be significantly upregulated in clear cell RCC [16, 22]. This evidence concerns the gene TDO2 and neoplasm.